Related by context. All words. (Click for frequent words.) 73 Chronic Lymphocytic Leukemia 73 Follicular Lymphoma 71 Glioblastoma Multiforme 71 Myelodysplastic Syndrome 71 B Cell Lymphoma 71 Relapsed Refractory 70 Cutaneous T 70 leukemia AML 70 Prolongs Survival 70 Chronic Myeloid Leukemia 70 Anthracycline 70 Advanced Renal Cell 70 Fludarabine 69 Diffuse Large B 69 Soft Tissue Sarcoma 69 Renal Cell Carcinoma 69 metastatic malignant 69 Decitabine 69 Adjuvant Treatment 69 Hsp# Inhibitor 69 Myelodysplastic Syndrome MDS 69 Hormone Refractory Prostate Cancer 69 Gastric Cancer 68 Improves Outcomes 68 Acute Myeloid Leukemia 68 Leukemias 68 Idiopathic Pulmonary Fibrosis 68 Metastatic Colorectal Cancer 68 Castration Resistant Prostate Cancer 68 Chronic Myelogenous Leukemia 68 Non Hodgkin Lymphoma 68 Tyrosine Kinase Inhibitor 67 Cyclophosphamide 67 Metastatic Melanoma 67 Neoadjuvant 67 Tyrosine Kinase Inhibitors 67 Peginterferon 67 Clinical Trial Results 67 Nilotinib 67 thalidomide Thalomid 67 Malignant Melanoma 67 Epratuzumab 67 refractory chronic lymphocytic 67 Previously Treated 67 Chronic Lymphocytic Leukemia CLL 67 Previously Untreated 67 leukemia CLL 67 Carcinoma 67 Randomized Study 67 ara C 67 Capecitabine 67 Myelofibrosis 67 Hodgkin lymphoma HL 67 Autoimmune Disease 67 Unresectable 66 Myelodysplastic Syndromes 66 CYT# potent vascular disrupting 66 Antitumor Activity 66 Oral Fingolimod 66 familial amyloidotic polyneuropathy FAP 66 Pegylated Interferon 66 Cardiotoxicity 66 Bladder Cancer 66 Irinotecan 66 recurrent glioblastoma multiforme 66 Cell Lymphoma 66 Meets Primary Endpoint 66 Predict Response 66 Improved Survival 66 Gastrointestinal Stromal Tumors 66 NMIBC 66 Pooled Analysis 66 Relapsed Refractory Aggressive 66 Clinical Outcome 66 Acute Myelogenous Leukemia AML 66 Hepatocellular Carcinoma 66 ErbB2 positive 66 Orally Active 66 Newly Diagnosed Multiple Myeloma 66 Acute Leukemia 66 Cell Non Hodgkin 66 Fulvestrant 66 Relapsing Multiple Sclerosis 66 imatinib Gleevec ® 66 Kinase Inhibitors 66 Lupus Nephritis 66 NSABP B 66 Acute Myelogenous Leukemia 66 Chronic Hepatitis C 65 Relapsing Remitting Multiple Sclerosis 65 Advanced Colorectal Cancer 65 Adjuvant Therapy 65 CTAP# Capsules 65 Anti Tumor 65 lymphocytic leukemia 65 Severe Sepsis 65 thymoma 65 HCV Protease Inhibitor 65 Lymphoid 65 Bevacizumab 65 Phase 2b Clinical Trial 65 Acute Myeloid Leukaemia AML 65 Adjuvant Chemotherapy 65 Etanercept 65 Metastatic 65 Anaplastic 65 Pemetrexed 65 Newly Diagnosed 65 Advanced Melanoma 65 Phase III Trial 65 HDAC Inhibitor 65 Combo Therapy 65 relapsing remitting MS RRMS 65 Abiraterone Acetate 65 Pertuzumab 65 Refractory Hodgkin Lymphoma 65 Investigational Treatment 65 Systemic Sclerosis 65 gefitinib Iressa 65 Patients Treated With 65 Receives Orphan Drug Designation 65 Acute Heart Failure 65 Radioimmunotherapy 65 Novel Oral 65 Malignant Glioma 65 Stomach Cancer 65 Bosutinib 65 Lenalidomide 65 Anti Tumor Activity 65 metastatic renal cell carcinoma 65 metastatic colorectal 65 antibody MAb 65 Study Evaluating 65 Annamycin 65 Philadelphia Chromosome Positive 65 HER2 Positive 65 Improves Survival 65 Subtypes 65 Investigational Drug 65 Peginterferon alfa 2b 65 Complicated Skin 65 stage IIIb IV 65 T Cell Lymphoma 65 Non Hodgkin 65 Atypical Hemolytic Uremic Syndrome 65 SPRYCEL ® 65 Chemoradiation 65 Hematological Malignancies 65 Drug Candidate 65 Survival Benefit 65 acute myeloid 64 Lymphocytic 64 stage IIIB 64 CLL SLL 64 Cholangiocarcinoma 64 dasatinib Sprycel 64 5 Fluorouracil 64 Aurora Kinase 64 Safinamide 64 cancer mCRC 64 Chronic Sinusitis 64 relapsed MM 64 Myeloma Patients 64 Meta Analysis 64 multiple myeloma MM 64 Patients Receiving 64 Metastatic Prostate Cancer 64 Targeted Therapy 64 Nucleoside 64 Shows Efficacy 64 histone deacetylase HDAC inhibitor 64 Fluorouracil 64 Enzyme Replacement Therapy 64 relapsed leukemia 64 Diabetic Foot Ulcer 64 Pirfenidone 64 Antigen Specific 64 Hepatocellular 64 biliary tract cancer 64 Bronchiectasis 64 Monotherapy 64 Rheumatoid Arthritis Drug 64 RNAi Therapeutic 64 Endometrial Cancer 64 Pulmonary Arterial Hypertension 64 FOLFOX6 64 advanced hepatocellular carcinoma 64 Breast Cancer Recurrence 64 essential thrombocythemia ET 64 Pharmacokinetics PK 64 Drug Shows Promise 64 metastatic renal 64 LHRH receptor positive 64 Renal Cancer 64 metastatic gastric 64 Glioma 64 Multiple Myeloma Patients 64 severe oral mucositis 64 Anticancer Drug 64 malignant lymphoma 64 Knee Osteoarthritis 64 Randomized Phase II 64 Aflibercept 64 Autoimmune Diseases 64 Vitro Activity 64 Myeloid 64 cell acute lymphoblastic 64 Placebo Controlled Trial 64 Multiple Myeloma 64 malignant ascites 64 cell lymphoma CTCL 64 receptor tyrosine kinase inhibitor 64 Immunosuppression 64 Newly Diagnosed Patients 64 Completes Patient Enrollment 64 Hormone Receptor Positive 64 Combination REOLYSIN R 64 Naive Patients 64 Epstein Barr Virus 64 II Clinical Trial 64 Plaque Psoriasis 64 Zarnestra 64 Lung Cancer Drug 64 Acute Myeloid Leukemia AML 64 mRCC 64 Dasatinib 63 Low Dose 63 Combination Therapy 63 Personalized Immunotherapy 63 ISTODAX ® 63 cholangiocarcinoma 63 Treatment Resistant 63 Pegylated Liposomal Doxorubicin 63 Romiplostim 63 Cyclooxygenase 2 63 Antitumor activity 63 Preclinical Study 63 resistant hormone refractory 63 Oral Mucositis 63 GW# [003] 63 Estrogen Receptor 63 Gefitinib 63 Allogeneic 63 Randomized Double Blind 63 Carcinoid 63 precursor acute lymphoblastic 63 Chronic lymphocytic leukemia 63 Metastatic Renal Cell Carcinoma 63 erlotinib Tarceva ® 63 Doxil ® 63 Hepatocellular Carcinoma HCC 63 relapsing multiple sclerosis 63 Temsirolimus 63 Vidaza azacitidine 63 HuMax EGFr 63 Immunotherapeutic 63 Sipuleucel T 63 nonmetastatic 63 Subgroup Analysis 63 dual endothelin receptor antagonist 63 Azacitidine 63 Degarelix 63 Ozarelix 63 Progenitor Cells 63 Mouse Model 63 Metastases 63 HER2 Positive Breast Cancer 63 Amrubicin 63 Epidermal Growth Factor Receptor 63 malignant pleural mesothelioma 63 dasatinib Sprycel ® 63 Rheumatoid Arthritis Patients 63 Ulcerative Colitis 63 Rheumatoid 63 Velcade bortezomib 63 pancreatic adenocarcinoma 63 Acute myeloid leukemia 63 Papillary 63 nilotinib Tasigna 63 Targeted Therapies 63 Bone Metastases 63 Disease Progression 63 EGFR TKI 63 Cimzia ® certolizumab pegol 63 gastrointestinal stromal tumor 63 AA Amyloidosis 63 Localized Prostate Cancer 63 interstitial cystitis IC 63 PEG IFN 63 Paroxysmal Nocturnal Hemoglobinuria PNH 63 castrate resistant prostate cancer 63 advanced metastatic renal 63 Kinase Inhibitor 63 PKC# 63 Tumor Response 63 Squamous 63 HER2 overexpression 63 Antiviral Therapy 63 Antiangiogenic 63 Pivotal Study 63 Novel Therapeutic 63 lymphoid malignancies 63 Fibrosis 63 Triapine 63 Acute Renal Failure 63 urothelial carcinoma 63 Bayer Nexavar 63 Heart Failure Patients 63 systemic anaplastic large 63 Analytical Tool 63 leukemia ALL 63 Metastatic Breast Cancer 63 Initiates Clinical Trial 63 Antisoma AS# 63 Melphalan 63 metastatic bladder 63 sunitinib Sutent 63 cetuximab Erbitux R 63 transplantation HCT 63 recurrent NSCLC 63 Chemotherapy Induced 63 Biologic Therapy 63 Rituximab 63 Advanced Prostate Cancer 63 Aliskiren 63 Crohn disease CD 63 Factor Receptor 63 Monoclonal Antibody 63 demethylating agent 63 vincristine doxorubicin 63 follicular lymphoma FL 63 carcinoid tumors 63 Natalizumab 63 Bortezomib 63 Xelox 63 Paclitaxel Carboplatin 63 Omacetaxine 63 Breast Cancers 63 Clofarabine 63 Nexavar sorafenib 62 Successfully Completes Phase 62 ZACTIMA 62 Adenocarcinoma 62 idiopathic thrombocytopenic purpura ITP 62 JAK Inhibitor 62 Juvenile Idiopathic Arthritis 62 Beta Amyloid 62 CML CP 62 adalimumab Humira 62 Phase IIb Trial 62 Liver Metastases 62 Phase 2a Clinical Trial 62 Oral Formulation 62 Multiple Myeloma MM 62 Overactive Bladder 62 Glufosfamide 62 Polycythemia Vera 62 Long Term Efficacy 62 Treating Chronic 62 Pralatrexate 62 Relapsed Refractory Multiple Myeloma 62 sorafenib Nexavar 62 Placebo Controlled Study 62 Significantly Improved 62 Emerging Therapies 62 Prospective Randomized 62 mycosis fungoides 62 Erlotinib 62 Carcinomas 62 Relapsed 62 epithelial tumors 62 Dupuytren Contracture 62 Diabetic Neuropathy 62 Slow Progression 62 Cancer Res 62 Angiotensin Converting Enzyme 62 Solid Tumors 62 Epoetin Alfa 62 Kidney Transplant Patients 62 Chronic Heart Failure 62 HER2 positive metastatic breast 62 Rheumatoid Arthritis RA 62 Parathyroid Hormone 62 TEMODAL 62 Diabetic Nephropathy 62 estramustine 62 Adenomas 62 PNP inhibitor 62 Malignancies 62 Metastatic Pancreatic Cancer 62 Radical Prostatectomy 62 fallopian tube carcinoma 62 Recombinant Human 62 ovarian carcinoma 62 papillary renal cell carcinoma 62 Infected Patients 62 Demonstrates Significant 62 Trial Evaluating 62 Therapy Evaluation 62 BRIM2 62 Stage IIB 62 Disease Modifying 62 Severe Asthma 62 Voreloxin 62 Granted Orphan Drug 62 Ibritumomab Tiuxetan 62 Sapacitabine 62 evaluating picoplatin 62 tyrosine kinase inhibitors TKIs 62 Hepatitis C Virus 62 Cytotoxic 62 Hyperlipidemia 62 Lung Cancer Survival 62 Presents Preclinical Data 62 pegylated liposomal doxorubicin 62 Lung Cancer Patients 62 Neurol 62 indolent follicular non 62 metastatic GIST 62 Interferon Beta 62 SSc 62 Node Positive 62 Neoplasms 62 smoldering multiple myeloma 62 Prostatic 62 Renal Anemia 62 alefacept 62 colorectal liver metastases 62 Cell Lung Cancer 62 pan HDAC inhibitor 62 hematopoietic cancers 62 Insulin Resistance 62 Cloretazine ® 62 SUTENT ® 62 Relapsed Multiple Myeloma 62 targeted radiotherapeutic 62 Diabetic Patients 62 Investigational Compound 62 Multicenter Study 62 anaplastic astrocytoma 62 chronic myeloid 62 refractory myeloma 62 Pathway Inhibitor 62 gastrointestinal stromal tumors GIST 62 Preclinical Models 62 Ankylosing Spondylitis 62 Trastuzumab 62 cinacalcet 62 Mg Usa 62 tumor xenograft models 62 bevacizumab Avastin ® 62 Benign Prostatic Hyperplasia 62 metastatic pancreatic 62 PEGylated Fab fragment 62 evaluating tivozanib 62 TNF Tumor Necrosis Factor 62 differentiated thyroid 62 Brentuximab Vedotin SGN 62 Patients Treated 62 Selective Inhibitor 62 demonstrated antitumor activity 62 Novel Treatments 62 refractory metastatic 62 Bezielle 62 Initiates Enrollment 62 Genes Predict 62 Carfilzomib 62 chronic eosinophilic leukemia 62 subependymal giant cell 62 Novel Compound 62 systemic fungal infections 62 HBeAg negative 62 Phase III Clinical Trial 62 Abstract Number 62 Initiate Phase 62 Neuroendocrine 62 Autologous Stem Cell Transplantation 62 Unfractionated Heparin 62 Exemestane 62 Pancreatic Adenocarcinoma 62 Gemcitabine 62 von Willebrand Disease 62 recurrent metastatic 62 Inflammatory Disease 62 Initiate Clinical Trial 62 Platinol ® 62 IL# PE#QQR 62 Enzastaurin 62 pediatric acute lymphoblastic 62 Cancer Incidence Mortality 62 Intracranial Aneurysms 62 tumors GIST 62 Stem Cell Transplant 62 Gleevec imatinib mesylate 62 huN# DM1 62 secondary hyperparathyroidism 61 follicular Non Hodgkin 61 Rheumatoid Arthritis 61 squamous cell carcinoma SCC 61 Systemic Lupus Erythematosus SLE 61 Randomized Double blind 61 standard chemotherapy regimen 61 Critical Limb Ischemia CLI 61 Autoimmune Disorders 61 Randomized Phase 61 5 fluorouracil leucovorin 61 complement inhibitor eculizumab 61 metastatic malignant melanoma 61 Interferon alfa 61 Golimumab 61 Epirubicin 61 CD3 monoclonal antibody 61 Circulating Tumor Cells 61 Chronic Prostatitis 61 Li Fraumeni Syndrome 61 Granulocyte Colony Stimulating Factor 61 unresectable stage 61 Inflammatory Diseases 61 myeloproliferative disorders 61 Synthetic Peptide 61 Improve Survival 61 ThermoDox R 61 Inflammatory Arthritis 61 Shows Promise Against 61 Tumor Growth 61 smoldering myeloma 61 Protease Inhibitors 61 MGd 61 cisplatin gemcitabine 61 Novel Inhibitor 61 refractory colorectal cancer 61 Myelodysplastic Syndromes MDS 61 Vicriviroc 61 essential thrombocythemia 61 Tumor Cell 61 Morquio 61 Breast Cancer Cells 61 Novel Mechanism 61 Chronic HCV 61 Advanced Solid Tumors 61 SCCHN 61 Bipolar Depression 61 Telbivudine 61 Lambert Eaton Myasthenic 61 unresectable inoperable 61 Dilated Cardiomyopathy 61 Radiofrequency Ablation 61 capecitabine Xeloda 61 5 FU leucovorin 61 Elderly Patients 61 Deforolimus 61 Pegylated 61 Treatment Regimen 61 refractory acute myeloid 61 mycophenolate mofetil 61 depsipeptide 61 Vicinium TM 61 Tumor Necrosis Factor 61 Cancer Vaccines 61 YONDELIS 61 Renal Artery 61 vinca alkaloid 61 Juvenile Rheumatoid Arthritis 61 Preclinical Data 61 Generalized Anxiety Disorder 61 metastatic colorectal carcinoma 61 colorectal carcinoma 61 Inflammatory Markers 61 FUSILEV enhances 61 peritumoral brain edema 61 Cloretazine 61 gastric carcinoma 61 Antisense Oligonucleotides 61 Anticancer Activity 61 Septic Shock 61 Demonstrates Potent 61 Progressive Multifocal Leukoencephalopathy 61 Fludara ® 61 Embolization 61 Hepatic Encephalopathy 61 prostate carcinoma 61 Controlled Trial 61 MabThera Rituxan 61 Dose Escalation 61 Androgen Deprivation 61 metastatic hormone refractory 61 Ambrisentan 61 generation purine nucleoside 61 mertansine 61 assessing T DM1 61 Ovarian Cancer Patients 61 angiogenesis inhibition 61 erythematosus 61 prostate cancer HRPC 61 Gene Linked 61 sunitinib Sutent ® 61 myelodysplastic syndrome MDS 61 recurrent glioblastoma 61 Breast Cancer Treatment 61 Secondary Hyperparathyroidism 61 atypical Hemolytic Uremic Syndrome 61 Neuroprotection 61 Kit CD# positive 61 Phase 2b Trial 61 galiximab 61 Ischemic 61 Investigational Agent 61 liposomal doxorubicin 61 Endocrinol 61 relapsed multiple myeloma 61 Files IND 61 Phase Ib Clinical Trial 61 Adefovir 61 Tocilizumab 61 myelodysplastic myeloproliferative diseases 61 Plus Ribavirin 61 Acute Lymphoblastic Leukemia 61 Receptor Antagonists 61 Evoltra ® 61 Dose Escalation Study 61 Present Preclinical Data 61 Acute Ischemic Stroke 61 Clostridium difficile Infection 61 monoclonal antibody conjugated 61 Enlarged Prostate 61 Abatacept 61 Initiates Clinical 61 acyclovir Lauriad R 61 haematologic 61 Hepatotoxicity 61 Mutation Analysis 61 Aggressive Prostate Cancer 61 Bosentan 61 Chemotherapeutic Agents 61 Psychiatric Disorders 61 Potent Anti 61 adriamycin 61 lymphoma leukemia 61 Thromboembolism 61 BARACLUDE ® 61 Breast Tumors 61 Squamous Cell Carcinoma 61 gastrointestinal stromal tumors 61 Interferon beta 61 Shows Promising 61 Nicotine Vaccine 61 Anticancer Drugs 61 Waldenstrom macroglobulinemia 61 Copegus ribavirin 61 Virologic 61 Slows Progression 61 Motesanib 61 Ceflatonin R 61 cyclophosphamide FC 61 Pediatric Patients 61 somatostatin analog 61 Chronic Hepatitis B 61 transthyretin TTR mediated amyloidosis 61 Hematologic 61 Romidepsin 61 metastatic neuroendocrine tumors 61 paclitaxel poliglumex 61 Liver Tumors 61 Hepatitis C Genotype 61 Hypertrophy 61 Asthma COPD 61 Invasive Fungal Infections 61 Single Dose 61 peritoneal carcinomatosis 61 JAK2 Inhibitor 61 Xanafide 61 INCB# [003] 61 allogeneic hematopoietic stem cell 61 Acute Lymphoblastic Leukaemia 61 Androgen Deprivation Therapy 61 IMiDs ® compound 61 acetonide FA 61 Drug Eluting 61 Lung Cancer Trial 61 Renal Impairment 61 dexamethasone Decadron 61 myeloproliferative neoplasms 61 gastrointestinal stromal tumor GIST 61 TO AVOID PREGNANCY WHILE 61 Paraplatin ® carboplatin 61 Temodar ® 61 Neovascular Age Related Macular 61 Ziprasidone 61 leukemia APL 61 Treatment Naive Patients 61 Polymerase Inhibitor 61 trastuzumab Herceptin ® 61 PEGylated interferon beta 1a 61 keloid scarring 61 Pancreatic Cancer 61 tocilizumab 61 Immunosuppressant 61 atypical hemolytic uremic syndrome 61 Gleevec resistant 61 Alemtuzumab 61 Sorafenib 61 TroVax ® 61 arthritis PsA 61 Therapeutic Vaccine 61 mGluR2 NAM 61 Carotid Stenting 61 Malignant Mesothelioma 60 ® lenalidomide 60 Anthrax Toxin 60 corticosteroid dexamethasone 60 hypereosinophilic syndrome 60 Renal Function 60 Therapy Improves 60 lung pancreatic 60 Interferon Alfa 60 MELAS 60 Phase 2a Trial 60 Ranolazine 60 relapsed acute lymphoblastic 60 oligodendrogliomas 60 beta 1a 60 relapsed refractory multiple myeloma 60 Roche Actemra 60 bladder carcinoma 60 Prognostic Significance 60 Cell Transplants 60 polycythemia vera essential thrombocythemia 60 paraganglioma 60 PSMA ADC 60 Janus Kinase 60 Preclinical Efficacy 60 Adjuvant Breast Cancer 60 recurrent GBM 60 alpha 2a 60 Antitumor 60 Tanespimycin 60 STRIDE PD 60 Tumor Progression 60 chemotherapy cisplatin 60 Submits NDA 60 Arrhythmogenic 60 Lubiprostone 60 alpha1 antitrypsin deficiency 60 Intravesical 60 cell carcinoma RCC 60 Folfox 60 aurora kinase 60 KRAS wild 60 Chronic lymphocytic leukemia CLL 60 superficial bladder cancer 60 Protease Inhibitor 60 Sirolimus Eluting Stent 60 metastatic castration resistant 60 CHOP chemotherapy 60 induces apoptosis 60 Treated Patients 60 oral prodrug 60 Chronic Myelogenous Leukemia CML 60 Presents Positive 60 sunitinib malate 60 Pharmacokinetic Study 60 glioblastoma multiforme GBM 60 Invasive Breast Cancer 60 JMML 60 Signaling Pathway 60 Pivotal Trials 60 Imatinib 60 fluoropyrimidine 60 Teva Provides Update 60 Skeletal Muscle 60 ON #.Na 60 Multicenter Phase 60 chronic granulomatous disease 60 Janus kinase 60 anthracycline containing 60 Patients Undergoing 60 Tipranavir 60 Phase IIa Clinical Trial 60 Vidofludimus 60 Pazopanib 60 basal cell carcinoma BCC 60 poly ADP ribose polymerase 60 Left Ventricular 60 Bazedoxifene 60 BRAF inhibitor 60 refractory cutaneous T 60 RhuDex 60 selective modulator 60 Cardiac Troponin 60 Oncol 60 Vascugel 60 Antiviral Activity 60 Bisphosphonate 60 registrational Phase 60 cisplatin resistant 60 Campath alemtuzumab 60 systemic mastocytosis 60 Prospective Randomized Trial 60 Therapeutic Targets 60 pT2 60 Acute Stroke 60 Renal Cell Cancer 60 Aortic Stenosis 60 acute leukemias 60 Neuroendocrine Tumors 60 Cellular Immunotherapy 60 papillary thyroid carcinoma 60 bendamustine 60 CD# CD# 60 Sustained Efficacy 60 myelofibrosis polycythemia vera 60 Torisel 60 Combination Treatment 60 Laryngeal Cancer 60 Intervention Effectiveness 60 Microalbuminuria 60 J Clin 60 intratumoral injection 60 Cytochrome P# 60 FDA Okays 60 acute myelogenous 60 Plecanatide 60 cutaneous squamous cell carcinoma 60 Major Depressive Disorder 60 paclitaxel Taxol R 60 Induction Chemotherapy 60 Pemphigus Vulgaris 60 Adalimumab 60 Multicenter Randomized 60 biochemical relapse 60 Quinamed 60 vidofludimus 60 Nexavar tablets 60 Adjunctive Therapy 60 PAOD 60 Intravitreal 60 Adenoma 60 Infliximab 60 Upregulation 60 Gemzar ® 60 cyclophosphamide methotrexate 60 Immunomedics Announces 60 Ribavirin causes 60 RENAL 60 Systemic lupus erythematosus SLE 60 Chronic Renal Failure 60 Randomized Clinical Trials 60 ankylosing spondylitis AS 60 temsirolimus 60 CTEPH 60 BRAF V#E 60 Completes Enrollment 60 Thromboembolic 60 irinotecan doxorubicin oxaliplatin paclitaxel 60 enzastaurin 60 FOLFOX6 chemotherapy regimen 60 Bevacizumab Avastin 60 Treatment Shows Promise 60 non splenectomized 60 Pivotal Phase III 60 Initiates Phase III 60 Acute Promyelocytic Leukemia 60 Complete Remission 60 R lenalidomide 60 Gaucher Disease 60 Colorectal Cancer Patients 60 Randomized Double Blind Placebo 60 Liver Failure 60 Mycophenolate Mofetil 60 hormone refractory 60 Randomized Phase III 60 Drug Combo 60 Attenuates 60 IRX 2 60 kidney urologic 60 heavily pretreated 60 Mitral Regurgitation 60 dose melphalan 60 Hemorrhagic Stroke 60 Congenital Emphysema 60 Appears Safe 60 Brain Metastases 60 Human Neural Stem 60 Leukocyte 60 Chronic Pelvic Pain 60 gemcitabine carboplatin 60 Cystectomy 60 ST Segment Elevation 60 remission induction 60 bevacizumab Avastin R 60 Mimetics 60 demethylation agents 60 Prostate Cancer Patients 60 Dapagliflozin 60 Paraplatin ® 60 Aptamer 60 IN PATIENTS WITH 60 Hematological Cancers 60 PF # [002] 60 Taxotere ® 60 Bendamustine 60 Prognostic Factors 60 Non Hodgkins Lymphoma 60 ABVD 60 Boosts Survival 60 Cancer Patients Treated 60 alfa 2a 60 trans retinoic acid 60 Aplidin 60 Aryplase 60 mCRC patients 60 Apoptotic 60 Chronic Myeloid Leukemia CML 60 BCG refractory carcinoma 60 Dyskinesia 60 chronic lymphocytic leukemia CLL 60 PRTX 60 Immune Responses 60 Phase 2b Study 60 gastric adenocarcinoma 60 Tesmilifene 60 Tolerability 60 doxorubicin cyclophosphamide 60 Eluting Stent 60 proteasome inhibitor 60 Pancreatic 60 cutaneous T 60 Efficacy Trial 60 CALGB # [002] 60 Mutational 60 prostate adenocarcinoma 60 ALN HPN 60 Cancer Treatments 60 IgG1 monoclonal antibody 60 ovarian pancreatic 60 IMiDs ® 60 cilengitide 60 T1c 60 malignant pleural mesothelioma MPM 60 irreversible inhibitor 60 interleukin IL -# 60 Ofatumumab 60 ACE Inhibitors 60 idiopathic pulmonary fibrosis IPF 60 gastrointestinal stromal tumors GISTs 60 Phase IIb Clinical Trial 60 Well Tolerated 60 Alzheimer Disease AD 60 Hypercholesterolemia 60 Adjuvant 60 Syndrome LEMS 60 Eculizumab 60 Accelerated Partial Breast Irradiation 60 CT Angiography 60 Hemodialysis Patients 60 Advanced Pancreatic Cancer 60 Statistically Significant 60 MEK Inhibitor 60 orally inhaled migraine 60 pertuzumab 60 haematological cancers 60 Phase III Trials 60 Solid Tumor 60 interferon gamma 1b 60 sodium glucose cotransporter 60 fludarabine cyclophosphamide 60 Esophageal Cancer 60 Cancer Immunotherapy 60 lenalidomide Revlimid R 60 unresectable tumors 60 melphalan prednisone 60 vascular disrupting agent 60 Tacrolimus 60 J Am Acad 60 Autologous 60 Anti TNF 60 prostate cancer CRPC 60 PARP Inhibitor 60 Idiopathic Pulmonary Fibrosis IPF 60 Occlusive Disease 60 nucleoside analog 60 Drug Prevents 60 Diagnostic Criteria 60 monoclonal anti 60 Clusterin 60 Thyroid Cancer 60 Adjunctive 60 Lamotrigine 60 pediatric malignancies 60 Prostate Cancer Treatment 60 RhuDex R 60 Patient Outcomes 60 Peripheral Artery Disease 60 medically inoperable 60 SNT-MC#/idebenone 60 RhuDex TM 60 docetaxel Taxotere ® 60 Efficacious 60 trabectedin